Epigenomics Financial Statements From 2010 to 2024

EPGNF Stock  USD 0.50  0.00  0.00%   
Epigenomics financial statements provide useful quarterly and yearly information to potential Epigenomics AG investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Epigenomics financial statements helps investors assess Epigenomics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Epigenomics' valuation are summarized below:
Epigenomics AG does not presently have any fundamental signals for analysis.
Check Epigenomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Epigenomics main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Epigenomics financial statements analysis is a perfect complement when working with Epigenomics Valuation or Volatility modules.
  
This module can also supplement various Epigenomics Technical models . Check out the analysis of Epigenomics Correlation against competitors.

Epigenomics Operating Margin Analysis

Epigenomics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

 = 

Operating Income

Revenue

X

100

More About Operating Margin | All Equity Analysis

Current Epigenomics Operating Margin

    
  (15.90) %  
Most of Epigenomics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Epigenomics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition

Based on the recorded statements, Epigenomics AG has an Operating Margin of -15.8959%. This is 54.69% lower than that of the Healthcare sector and 74.91% lower than that of the Diagnostics & Research industry. The operating margin for all United States stocks is 188.49% higher than that of the company.

Epigenomics AG Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Epigenomics's current stock value. Our valuation model uses many indicators to compare Epigenomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Epigenomics competition to find correlations between indicators driving Epigenomics's intrinsic value. More Info.
Epigenomics AG is one of the top stocks in earnings per share category among related companies. It is one of the top stocks in price to book category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Epigenomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Epigenomics' Pink Sheet . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Epigenomics' earnings, one of the primary drivers of an investment's value.

About Epigenomics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Epigenomics income statement, its balance sheet, and the statement of cash flows. Epigenomics investors use historical funamental indicators, such as Epigenomics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Epigenomics investors may use each financial statement separately, they are all related. The changes in Epigenomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Epigenomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Epigenomics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Epigenomics. Please read more on our technical analysis and fundamental analysis pages.
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 36 people.

Pair Trading with Epigenomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Epigenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Epigenomics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Epigenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Epigenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Epigenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Epigenomics AG to buy it.
The correlation of Epigenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Epigenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Epigenomics AG moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Epigenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out the analysis of Epigenomics Correlation against competitors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Epigenomics Pink Sheet analysis

When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Please note, there is a significant difference between Epigenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Epigenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Epigenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.